Pub Date : 2025-01-30eCollection Date: 2025-01-01DOI: 10.3389/fimmu.2025.1528707
Chun-Mei Wang, Ying-Jie Chen, Bo-Cheng Yang, Jia-Wen Yang, Wei Wang, Yang Zeng, Jun Jiang
Objective: People with Hashimoto's thyroiditis (HT) often have low vitamin D3 concentrations. Some research has suggested that vitamin D3 supplementation reduces thyroid inflammation, but this remains controversial.
Methods: EAT was induced in female NOD/ShiLtJ mice by giving them water containing 0.05% sodium iodide, and 1μg/kg of 1α,25-(OH)2D3 was injected intraperitoneally every other day. After 8 weeks, the morphological architecture of the mouse thyroid follicles was examined by histological sections, thyroid autoantibodies and thyroid hormone concentrations were determined by enzyme-linked immunosorbent assays (ELISAs), and the major functions and subsets of B- and T-lymphocytes in the mouse thyroid were determined by tissue multiple immunofluorescence technology and ELISA.
Results: EAT caused thyroiditis follicle destruction and interfollicular lymphocyte infiltration in mice, increased concentrations of circulating thyroid autoimmune antibodies TG-Ab and TPO-Ab, and abnormal thyroid hormone levels. EAT also increased the number and functionality of CD4+ Tfh, Th17,Th1 and Th2 cells in the thyroid, while decreasing the number and functionality of CD4+ Treg cells and CD19+B10 cells. Treatment with VD3 reversed these changes.
Conclusion: Vitamin D3 supplementation can effectively treat autoimmune thyroiditis in mice. VD3 reduces autoimmune thyroid damage and decreases serum thyroid antibody levels in mice by inhibiting the differentiation and functionality of pro-inflammatory Tfh, Th17, Th1 and Th2 cells and by facilitating the differentiation and functionality of anti-inflammatory B10 cells and Treg.
{"title":"Supplementation with active vitamin D3 ameliorates experimental autoimmune thyroiditis in mice by modulating the differentiation and functionality of intrathyroidal T-cell subsets.","authors":"Chun-Mei Wang, Ying-Jie Chen, Bo-Cheng Yang, Jia-Wen Yang, Wei Wang, Yang Zeng, Jun Jiang","doi":"10.3389/fimmu.2025.1528707","DOIUrl":"10.3389/fimmu.2025.1528707","url":null,"abstract":"<p><strong>Objective: </strong>People with Hashimoto's thyroiditis (HT) often have low vitamin D3 concentrations. Some research has suggested that vitamin D3 supplementation reduces thyroid inflammation, but this remains controversial.</p><p><strong>Methods: </strong>EAT was induced in female NOD/ShiLtJ mice by giving them water containing 0.05% sodium iodide, and 1μg/kg of 1α,25-(OH)<sub>2</sub>D<sub>3</sub> was injected intraperitoneally every other day. After 8 weeks, the morphological architecture of the mouse thyroid follicles was examined by histological sections, thyroid autoantibodies and thyroid hormone concentrations were determined by enzyme-linked immunosorbent assays (ELISAs), and the major functions and subsets of B- and T-lymphocytes in the mouse thyroid were determined by tissue multiple immunofluorescence technology and ELISA.</p><p><strong>Results: </strong>EAT caused thyroiditis follicle destruction and interfollicular lymphocyte infiltration in mice, increased concentrations of circulating thyroid autoimmune antibodies TG-Ab and TPO-Ab, and abnormal thyroid hormone levels. EAT also increased the number and functionality of CD4+ Tfh, Th17,Th1 and Th2 cells in the thyroid, while decreasing the number and functionality of CD4+ Treg cells and CD19<sup>+</sup>B10 cells. Treatment with VD3 reversed these changes.</p><p><strong>Conclusion: </strong>Vitamin D3 supplementation can effectively treat autoimmune thyroiditis in mice. VD3 reduces autoimmune thyroid damage and decreases serum thyroid antibody levels in mice by inhibiting the differentiation and functionality of pro-inflammatory Tfh, Th17, Th1 and Th2 cells and by facilitating the differentiation and functionality of anti-inflammatory B10 cells and Treg.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1528707"},"PeriodicalIF":5.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30eCollection Date: 2025-01-01DOI: 10.3389/fimmu.2025.1560546
Qinyuan Gong, Rongzhen Xu
[This corrects the article DOI: 10.3389/fimmu.2024.1533740.].
{"title":"Corrigendum: Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer.","authors":"Qinyuan Gong, Rongzhen Xu","doi":"10.3389/fimmu.2025.1560546","DOIUrl":"https://doi.org/10.3389/fimmu.2025.1560546","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fimmu.2024.1533740.].</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1560546"},"PeriodicalIF":5.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30eCollection Date: 2025-01-01DOI: 10.3389/fimmu.2025.1537651
Shubin Wang, Xiangjun Liu, Lu Xu, Jinyi Lang, Dengqun Liu
Introduction: Ulcerative colitis (UC) is a global gastrointestinal disease, which is mainly caused by both dysfunctional epithelial barrier and inflammation response. Iron is a critical fundamental element for both the maintenance of homeostasis and the mediation of inflammation in many tissues. However, the role and mechanism of iron in the phase of enteritis and the subsequent repairing phase of intestinal stem cells has not been elucidated. In this study, we aimed to explore whether and how iron depletion would affect the occurrence and outcome of experimental colitis.
Methods: Iron depletion was realized by deferoxamine (DFO) at either the early stage or late stage of dextran sulfate sodium (DSS) induced experimental colitis in mice. The gross images of colons, general health, histology, barrier integrity, and qRT-PCR were performed. Meanwhile, cell culture and colonic organoids were used to examine the influence of iron depletion in vitro. Signaling pathway and inflammatory infiltration were investigated by immunostaining.
Results: Iron depletion within the early stage of DSS treatment significantly inhibited the onset of the inflammatory response, maintained the integrity of the colonic epithelium, and preserved the activity of intestinal stem cells (ISCs) both in vivo and in vitro. However, both continuous iron depletion by DFO and late DFO treatment aggravated colonic injury and postponed the recovery from colitis. Early DFO-induced iron depletion was able to maintain the p-STAT3 and p-ERK1/2 signaling pathways within the colonic epithelium at the early phase of colitis, but late DFO treatment inhibited the activity of these two pathways.
Discussion: Our study demonstrated that the manipulation of iron depletion by DFO might greatly affect the outcomes of experimental colitis in a phase-dependent manner, which suggests that the balance of iron metabolism might be an effective therapeutic target for the clinical treatment of IBD patients.
{"title":"Phase-dependent iron depletion differentially regulates the niche of intestinal stem cells in experimental colitis via ERK/STAT3 signaling pathway.","authors":"Shubin Wang, Xiangjun Liu, Lu Xu, Jinyi Lang, Dengqun Liu","doi":"10.3389/fimmu.2025.1537651","DOIUrl":"10.3389/fimmu.2025.1537651","url":null,"abstract":"<p><strong>Introduction: </strong>Ulcerative colitis (UC) is a global gastrointestinal disease, which is mainly caused by both dysfunctional epithelial barrier and inflammation response. Iron is a critical fundamental element for both the maintenance of homeostasis and the mediation of inflammation in many tissues. However, the role and mechanism of iron in the phase of enteritis and the subsequent repairing phase of intestinal stem cells has not been elucidated. In this study, we aimed to explore whether and how iron depletion would affect the occurrence and outcome of experimental colitis.</p><p><strong>Methods: </strong>Iron depletion was realized by deferoxamine (DFO) at either the early stage or late stage of dextran sulfate sodium (DSS) induced experimental colitis in mice. The gross images of colons, general health, histology, barrier integrity, and qRT-PCR were performed. Meanwhile, cell culture and colonic organoids were used to examine the influence of iron depletion <i>in vitro</i>. Signaling pathway and inflammatory infiltration were investigated by immunostaining.</p><p><strong>Results: </strong>Iron depletion within the early stage of DSS treatment significantly inhibited the onset of the inflammatory response, maintained the integrity of the colonic epithelium, and preserved the activity of intestinal stem cells (ISCs) both <i>in vivo</i> and <i>in vitro</i>. However, both continuous iron depletion by DFO and late DFO treatment aggravated colonic injury and postponed the recovery from colitis. Early DFO-induced iron depletion was able to maintain the p-STAT3 and p-ERK1/2 signaling pathways within the colonic epithelium at the early phase of colitis, but late DFO treatment inhibited the activity of these two pathways.</p><p><strong>Discussion: </strong>Our study demonstrated that the manipulation of iron depletion by DFO might greatly affect the outcomes of experimental colitis in a phase-dependent manner, which suggests that the balance of iron metabolism might be an effective therapeutic target for the clinical treatment of IBD patients.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1537651"},"PeriodicalIF":5.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30eCollection Date: 2025-01-01DOI: 10.3389/fimmu.2025.1513966
Chaowei Song, Ying Huang, Fang Han, Zhiyong Wang
Introduction: The large yellow croaker iridovirus (LYCIV) poses a significant threat to the aquaculture industry of Larimichthys crocea. Understanding the host defense response to LYCIV infection is crucial for developing effective strategies to mitigate its impact.
Methods: In this study, an epigenetic approach was employed to investigate dynamic changes in chromatin accessibility using the assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq). Additionally, RNA sequencing (RNA-seq) was used to analyze the expression pattern of immune response genes upon LYCIV infection.
Results: Substantial alterations in chromatin accessibility were observed, particularly in the regulatory regions of key immune-related genes. Significant changes in the expression of AP-1 transcription factors, including the Batf gene, were noted. CUT&Tag results revealed that AP-1 was significantly enriched in the open chromatin regions of cytokine genes, with Batf potentially regulating the cytokine genes LIF and CLCF1.
Discussion: These findings suggest that AP-1 may play a crucial role in the defense response against viral infection by modulating inflammatory cytokines and contributing to cellular inflammatory responses. This study provides a comprehensive analysis of the epigenomic landscape and gene expression regulation during iridovirus infection in L. crocea, offering valuable insights for breeding programs aimed at combating iridovirus infections.
{"title":"Chromatin accessibility and differentially expressed genes profiling in large yellow croaker (<i>Larimichthys crocea</i>) head kidney cells following iridovirus infection.","authors":"Chaowei Song, Ying Huang, Fang Han, Zhiyong Wang","doi":"10.3389/fimmu.2025.1513966","DOIUrl":"10.3389/fimmu.2025.1513966","url":null,"abstract":"<p><strong>Introduction: </strong>The large yellow croaker iridovirus (LYCIV) poses a significant threat to the aquaculture industry of <i>Larimichthys crocea</i>. Understanding the host defense response to LYCIV infection is crucial for developing effective strategies to mitigate its impact.</p><p><strong>Methods: </strong>In this study, an epigenetic approach was employed to investigate dynamic changes in chromatin accessibility using the assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq). Additionally, RNA sequencing (RNA-seq) was used to analyze the expression pattern of immune response genes upon LYCIV infection.</p><p><strong>Results: </strong>Substantial alterations in chromatin accessibility were observed, particularly in the regulatory regions of key immune-related genes. Significant changes in the expression of AP-1 transcription factors, including the <i>Batf</i> gene, were noted. CUT&Tag results revealed that AP-1 was significantly enriched in the open chromatin regions of cytokine genes, with <i>Batf</i> potentially regulating the cytokine genes <i>LIF</i> and <i>CLCF1</i>.</p><p><strong>Discussion: </strong>These findings suggest that AP-1 may play a crucial role in the defense response against viral infection by modulating inflammatory cytokines and contributing to cellular inflammatory responses. This study provides a comprehensive analysis of the epigenomic landscape and gene expression regulation during iridovirus infection in <i>L. crocea</i>, offering valuable insights for breeding programs aimed at combating iridovirus infections.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1513966"},"PeriodicalIF":5.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30eCollection Date: 2025-01-01DOI: 10.3389/fimmu.2025.1516848
Qian Li, Tong Zhang, Shan Yao, Feifei Gao, Lisha Nie, Hehan Tang, Bin Song, Yi Wei
Objectives: To explore whether T1 mapping parameters and the functional liver imaging score (FLIS) based on Gd-EOB-DTPA MRI could evaluate liver regeneration after hepatectomy for HCC patient.
Methods: This retrospective study finally included 60 HCC patients (48 men and 12 women, with a median age of 53 years). T1 relaxation time of liver before gadoxetic acid injection (T1pre) and during the hepatobiliary phase (T1HBP), reduction rate (Δ%) and FLIS were calculated, their correlations with liver fibrosis stage, hepatic steatosis, and liver regeneration, quantified as regeneration index (RI), were assessed by Kendall's tau-b correlation test or Spearman's correlation test. Multivariate linear regression analyses were used to explore the indicator of RI.
Results: T1pre, T1HBP, Δ%, and FLIS manifested significant correlation with fibrosis stage (r = 0.434, P =0.001; r = 0.546, P < 0.001; r = -0.356, P =0.005; r = -0.653, P <0.001, respectively). T1pre showed significant correction with steatosis grade (r = 0.415, P =0.001). Fibrosis stage and steatosis grade were associated with RI (r = -0.436, P<0.001; r = -0.338, P =0.008). Accordingly, T1pre, T1HBP and FLIS were the significant predictors (P<0.05) of RI in multivariate analysis. Similarly, in the patients undergoing minor hepatectomy (n=35), T1HBP, Δ% and FLIS were related to RI (P<0.05) in multivariate analysis. Nevertheless, in the patients undergoing major hepatectomy (n=25), no T1 mapping parameter and FLIS was the independent predictor of RI.
Conclusions: T1 mapping parameters and FLIS were the potential noninvasive indicators of liver regeneration, except for HCC patients undergoing major hepatectomy.
Clinical relevance statement: The value of T1 mapping and FLIS with Gd-EOB-DTPA MRI for accurate preoperative evaluation of liver regeneration is critical to prevent liver failure and improve prognosis of HCC patients.
{"title":"Preoperative assessment of liver regeneration using T1 mapping and the functional liver imaging score derived from Gd-EOB-DTPA-enhanced magnetic resonance for patient with hepatocellular carcinoma after hepatectomy.","authors":"Qian Li, Tong Zhang, Shan Yao, Feifei Gao, Lisha Nie, Hehan Tang, Bin Song, Yi Wei","doi":"10.3389/fimmu.2025.1516848","DOIUrl":"10.3389/fimmu.2025.1516848","url":null,"abstract":"<p><strong>Objectives: </strong>To explore whether T1 mapping parameters and the functional liver imaging score (FLIS) based on Gd-EOB-DTPA MRI could evaluate liver regeneration after hepatectomy for HCC patient.</p><p><strong>Methods: </strong>This retrospective study finally included 60 HCC patients (48 men and 12 women, with a median age of 53 years). T1 relaxation time of liver before gadoxetic acid injection (T1<sub>pre</sub>) and during the hepatobiliary phase (T1<sub>HBP</sub>), reduction rate (Δ%) and FLIS were calculated, their correlations with liver fibrosis stage, hepatic steatosis, and liver regeneration, quantified as regeneration index (RI), were assessed by Kendall's tau-b correlation test or Spearman's correlation test. Multivariate linear regression analyses were used to explore the indicator of RI.</p><p><strong>Results: </strong>T1<sub>pre</sub>, T1<sub>HBP</sub>, Δ%, and FLIS manifested significant correlation with fibrosis stage (r = 0.434, <i>P</i> =0.001; r = 0.546, <i>P</i> < 0.001; r = -0.356, <i>P</i> =0.005; r = -0.653, <i>P <</i>0.001, respectively). T1<sub>pre</sub> showed significant correction with steatosis grade (r = 0.415, <i>P</i> =0.001). Fibrosis stage and steatosis grade were associated with RI (r = -0.436, <i>P</i><0.001; r = -0.338, <i>P</i> =0.008). Accordingly, T1<sub>pre</sub>, T1<sub>HBP</sub> and FLIS were the significant predictors (<i>P</i><0.05) of RI in multivariate analysis. Similarly, in the patients undergoing minor hepatectomy (n=35), T1<sub>HBP</sub>, Δ% and FLIS were related to RI (<i>P</i><0.05) in multivariate analysis. Nevertheless, in the patients undergoing major hepatectomy (n=25), no T1 mapping parameter and FLIS was the independent predictor of RI.</p><p><strong>Conclusions: </strong>T1 mapping parameters and FLIS were the potential noninvasive indicators of liver regeneration, except for HCC patients undergoing major hepatectomy.</p><p><strong>Clinical relevance statement: </strong>The value of T1 mapping and FLIS with Gd-EOB-DTPA MRI for accurate preoperative evaluation of liver regeneration is critical to prevent liver failure and improve prognosis of HCC patients.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1516848"},"PeriodicalIF":5.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30eCollection Date: 2025-01-01DOI: 10.3389/fimmu.2025.1494446
Metoboroghene O Mowoe, Hisham Allam, Joshua Nqada, Marc Bernon, Karan Gandhi, Sean Burmeister, Urda Kotze, Miriam Kahn, Christo Kloppers, Suba Dharshanan, Zafirah Azween, Pamela Maimela, Paul Townsend, Eduard Jonas, Jonathan M Blackburn
Introduction: New biomarkers are urgently needed to detect pancreatic ductal adenocarcinoma (PDAC) at an earlier stage for individualized treatment strategies and to improve outcomes. Autoantibodies (AAbs) in principle make attractive biomarkers as they arise early in disease, report on disease-associated perturbations in cellular proteomes, and are static in response to other common stimuli, yet are measurable in the periphery, potentially well in advance of the onset of clinical symptoms.
Methods: Here, we used high-throughput, custom cancer antigen microarrays to identify a clinically relevant autoantibody biomarker combination able to differentially detect PDAC. Specifically, we quantified the serological AAb profiles of 94 PDAC, chronic pancreatitis (CP), other pancreatic- (PC) and prostate cancers (PRC), non-ulcer dyspepsia patients (DYS), and healthy controls (HC).
Results: Combinatorial ROC curve analysis on the training cohort data from the cancer antigen microarrays identified the most effective biomarker combination as CEACAM1-DPPA2-DPPA3-MAGEA4-SRC-TPBG-XAGE3 with an AUC = 85·0% (SE = 0·828, SP = 0·684). Additionally, differential expression analysis on the samples run on the iOme™ array identified 4 biomarkers (ALX1-GPA33-LIP1-SUB1) upregulated in PDAC against diseased and healthy controls. Identified AAbs were validated in silico using public immunohistochemistry datasets and experimentally using a custom PDAC protein microarray comprising the 11 optimal AAb biomarker panel. The clinical utility of the biomarker panel was tested in an independent cohort comprising 223 PDAC, PC, PRC, colorectal cancer (CRC), and HC samples. Combinatorial ROC curve analysis on the validation data identified the most effective biomarker combination to be CEACAM1-DPPA2-DPPA3-MAGEA4-SRC-TPBG-XAGE3 with an AUC = 85·0% (SE = 0·828, SP = 0·684). Subsequently, the specificity of the 11-biomarker panel was validated against other cancers (PDAC vs PC: AUC = 70·3%; PDAC vs CRC: AUC = 84·3%; PDAC vs PRC: AUC = 80·2%) and healthy controls (PDAC vs HC: AUC = 80·9%), confirming that this novel AAb biomarker panel is able to selectively detect PDAC amongst other confounding diseases.
Conclusion: This AAb panel may therefore have the potential to form the basis of a novel diagnostic test for PDAC.
{"title":"Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma.","authors":"Metoboroghene O Mowoe, Hisham Allam, Joshua Nqada, Marc Bernon, Karan Gandhi, Sean Burmeister, Urda Kotze, Miriam Kahn, Christo Kloppers, Suba Dharshanan, Zafirah Azween, Pamela Maimela, Paul Townsend, Eduard Jonas, Jonathan M Blackburn","doi":"10.3389/fimmu.2025.1494446","DOIUrl":"10.3389/fimmu.2025.1494446","url":null,"abstract":"<p><strong>Introduction: </strong>New biomarkers are urgently needed to detect pancreatic ductal adenocarcinoma (PDAC) at an earlier stage for individualized treatment strategies and to improve outcomes. Autoantibodies (AAbs) in principle make attractive biomarkers as they arise early in disease, report on disease-associated perturbations in cellular proteomes, and are static in response to other common stimuli, yet are measurable in the periphery, potentially well in advance of the onset of clinical symptoms.</p><p><strong>Methods: </strong>Here, we used high-throughput, custom cancer antigen microarrays to identify a clinically relevant autoantibody biomarker combination able to differentially detect PDAC. Specifically, we quantified the serological AAb profiles of 94 PDAC, chronic pancreatitis (CP), other pancreatic- (PC) and prostate cancers (PRC), non-ulcer dyspepsia patients (DYS), and healthy controls (HC).</p><p><strong>Results: </strong>Combinatorial ROC curve analysis on the training cohort data from the cancer antigen microarrays identified the most effective biomarker combination as CEACAM1-DPPA2-DPPA3-MAGEA4-SRC-TPBG-XAGE3 with an AUC = 85·0% (SE = 0·828, SP = 0·684). Additionally, differential expression analysis on the samples run on the iOme™ array identified 4 biomarkers (ALX1-GPA33-LIP1-SUB1) upregulated in PDAC against diseased and healthy controls. Identified AAbs were validated in silico using public immunohistochemistry datasets and experimentally using a custom PDAC protein microarray comprising the 11 optimal AAb biomarker panel. The clinical utility of the biomarker panel was tested in an independent cohort comprising 223 PDAC, PC, PRC, colorectal cancer (CRC), and HC samples. Combinatorial ROC curve analysis on the validation data identified the most effective biomarker combination to be CEACAM1-DPPA2-DPPA3-MAGEA4-SRC-TPBG-XAGE3 with an AUC = 85·0% (SE = 0·828, SP = 0·684). Subsequently, the specificity of the 11-biomarker panel was validated against other cancers (PDAC vs PC: AUC = 70·3%; PDAC vs CRC: AUC = 84·3%; PDAC vs PRC: AUC = 80·2%) and healthy controls (PDAC vs HC: AUC = 80·9%), confirming that this novel AAb biomarker panel is able to selectively detect PDAC amongst other confounding diseases.</p><p><strong>Conclusion: </strong>This AAb panel may therefore have the potential to form the basis of a novel diagnostic test for PDAC.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1494446"},"PeriodicalIF":5.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30eCollection Date: 2025-01-01DOI: 10.3389/fimmu.2025.1557929
Yaroslav Ugolkov, Antonina Nikitich, Cristina Leon, Gabriel Helmlinger, Kirill Peskov, Victor Sokolov, Alina Volkova
[This corrects the article DOI: 10.3389/fimmu.2024.1371620.].
{"title":"Corrigendum: Mathematical modeling in autoimmune diseases: from theory to clinical application.","authors":"Yaroslav Ugolkov, Antonina Nikitich, Cristina Leon, Gabriel Helmlinger, Kirill Peskov, Victor Sokolov, Alina Volkova","doi":"10.3389/fimmu.2025.1557929","DOIUrl":"https://doi.org/10.3389/fimmu.2025.1557929","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fimmu.2024.1371620.].</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1557929"},"PeriodicalIF":5.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30eCollection Date: 2025-01-01DOI: 10.3389/fimmu.2025.1531447
Michael Hecker, Brit Fitzner, Isis Ludwig-Portugall, Friederike Bohne, Edmar Heyland, Juliane Klehmet, Matthias Grothe, Matthias Schwab, Alexander Winkelmann, Stefanie Meister, Ales Dudesek, Hannah Wurm, Ilya Ayzenberg, Ingo Kleiter, Corinna Trebst, Martin W Hümmert, Bernhard Neumann, Klaus Eulitz, Dirk Koczan, Uwe K Zettl
<p><strong>Background: </strong>High-dose glucocorticoids are the standard treatment for acute relapses in patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). Therapeutic apheresis can be considered for the escalation of relapse therapy, but some patients still do not recover sufficiently. We aimed to explore the effects of apheresis on humoral and cellular immune parameters and to identify features that correlate with beneficial clinical outcomes.</p><p><strong>Methods: </strong>We studied two cohorts comprising a total of 63 patients with MS or NMOSD who were undergoing relapse therapy with either methylprednisolone or apheresis. Blood samples were collected immediately before and after therapy to isolate plasma or serum as well as immune cells. We then measured (1) concentrations of the immunoglobulin isotypes IgG, IgM and IgA, (2) antibody reactivities against 12 peptides derived from potential autoantigens and Epstein-Barr virus proteins, (3) frequencies of CD19<sup>+</sup> B cells, CD3<sup>+</sup> T cells and CD14<sup>+</sup> monocytes, (4) transcriptome profiles of CD19<sup>+</sup> B cells and CD4<sup>+</sup> T cells and (5) mRNA levels of 7 cytotoxicity-related genes in CD4<sup>+</sup> T cells. The data were compared with regard to changes under therapy and with regard to differences between clinical responders and non-responders.</p><p><strong>Results: </strong>The initial therapy with methylprednisolone had no significant effect on immunoglobulin levels and (auto)antibody reactivities (<i>n</i> <sub>max</sub>=27 MS patients). In contrast, MS patients who underwent apheresis (<i>n</i> <sub>max</sub>=27) showed strong immunoglobulin reduction rates, especially for IgG, and decreased antibody reactivities against all tested peptides. EBNA1 (amino acids 391-410) was the only peptide that also reached the significance level in NMOSD patients (<i>n</i>=9). Non-responders to apheresis (<i>n</i>=12) had on average higher anti-EBNA1 (391-410) reactivities than responders (<i>n</i>=24) at baseline. Apheresis also led to a decrease in the proportion of monocytes, an increase in the proportion of T cells (<i>n</i>=29 patients with MS or NMOSD) and moderate transcriptome changes (<i>n</i> <sub>max</sub>=4 MS patients). A gene expression signature that is characteristic of CD4<sup>+</sup> cytotoxic T lymphocytes (CD4-CTLs) was found to be elevated at baseline in non-responders to apheresis, although this could not be validated with statistical significance (<i>n</i>=19 MS patients).</p><p><strong>Conclusion: </strong>Our data reveal that therapeutic apheresis in MS rapidly leads to a significant decrease in IgG reactivities against EBNA1 (391-410) and cross-reactive targets such as GlialCAM (370-389) and also has an impact on the gene expression of B cells and T cells. Further studies are required to verify whether anti-EBNA1 (391-410) antibody reactivities and the expression of CD4-CTL-related genes may be indica
{"title":"Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators.","authors":"Michael Hecker, Brit Fitzner, Isis Ludwig-Portugall, Friederike Bohne, Edmar Heyland, Juliane Klehmet, Matthias Grothe, Matthias Schwab, Alexander Winkelmann, Stefanie Meister, Ales Dudesek, Hannah Wurm, Ilya Ayzenberg, Ingo Kleiter, Corinna Trebst, Martin W Hümmert, Bernhard Neumann, Klaus Eulitz, Dirk Koczan, Uwe K Zettl","doi":"10.3389/fimmu.2025.1531447","DOIUrl":"10.3389/fimmu.2025.1531447","url":null,"abstract":"<p><strong>Background: </strong>High-dose glucocorticoids are the standard treatment for acute relapses in patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). Therapeutic apheresis can be considered for the escalation of relapse therapy, but some patients still do not recover sufficiently. We aimed to explore the effects of apheresis on humoral and cellular immune parameters and to identify features that correlate with beneficial clinical outcomes.</p><p><strong>Methods: </strong>We studied two cohorts comprising a total of 63 patients with MS or NMOSD who were undergoing relapse therapy with either methylprednisolone or apheresis. Blood samples were collected immediately before and after therapy to isolate plasma or serum as well as immune cells. We then measured (1) concentrations of the immunoglobulin isotypes IgG, IgM and IgA, (2) antibody reactivities against 12 peptides derived from potential autoantigens and Epstein-Barr virus proteins, (3) frequencies of CD19<sup>+</sup> B cells, CD3<sup>+</sup> T cells and CD14<sup>+</sup> monocytes, (4) transcriptome profiles of CD19<sup>+</sup> B cells and CD4<sup>+</sup> T cells and (5) mRNA levels of 7 cytotoxicity-related genes in CD4<sup>+</sup> T cells. The data were compared with regard to changes under therapy and with regard to differences between clinical responders and non-responders.</p><p><strong>Results: </strong>The initial therapy with methylprednisolone had no significant effect on immunoglobulin levels and (auto)antibody reactivities (<i>n</i> <sub>max</sub>=27 MS patients). In contrast, MS patients who underwent apheresis (<i>n</i> <sub>max</sub>=27) showed strong immunoglobulin reduction rates, especially for IgG, and decreased antibody reactivities against all tested peptides. EBNA1 (amino acids 391-410) was the only peptide that also reached the significance level in NMOSD patients (<i>n</i>=9). Non-responders to apheresis (<i>n</i>=12) had on average higher anti-EBNA1 (391-410) reactivities than responders (<i>n</i>=24) at baseline. Apheresis also led to a decrease in the proportion of monocytes, an increase in the proportion of T cells (<i>n</i>=29 patients with MS or NMOSD) and moderate transcriptome changes (<i>n</i> <sub>max</sub>=4 MS patients). A gene expression signature that is characteristic of CD4<sup>+</sup> cytotoxic T lymphocytes (CD4-CTLs) was found to be elevated at baseline in non-responders to apheresis, although this could not be validated with statistical significance (<i>n</i>=19 MS patients).</p><p><strong>Conclusion: </strong>Our data reveal that therapeutic apheresis in MS rapidly leads to a significant decrease in IgG reactivities against EBNA1 (391-410) and cross-reactive targets such as GlialCAM (370-389) and also has an impact on the gene expression of B cells and T cells. Further studies are required to verify whether anti-EBNA1 (391-410) antibody reactivities and the expression of CD4-CTL-related genes may be indica","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1531447"},"PeriodicalIF":5.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30eCollection Date: 2025-01-01DOI: 10.3389/fimmu.2025.1525736
Danyang Zhang, Bingxue Zhang
Gynecological cancers, including cervical, ovarian, and endometrial malignancies, remain a significant global health burden, exacerbated by disparities in access to preventive measures such as HPV vaccination and routine screening. The cGAS/STING signaling pathway, a pivotal mechanism in innate immunity, detects cytosolic DNA from pathogens or cellular damage, triggering immune responses via type I interferons and inflammatory cytokines. This pathway's dual role in gynecological cancers, either promoting antitumor immunity or facilitating tumor immune evasion, makes it a compelling target for innovative therapies. The article outlines cGAS/STING's influence on tumor microenvironments, immune surveillance, and inflammation, with emphasis on molecular mechanisms driving cancer progression. It explores interactions between DNA damage response pathways and immune modulation, highlighting the impact of cGAS/STING activation or suppression in ovarian, cervical, and endometrial cancers. The therapeutic potential of STING agonists, PARP inhibitors, and targeted immunotherapies is reviewed, demonstrating how these approaches can boost immune responses, counteract chemotherapy resistance, and improve patient outcomes. The study also discusses strategies for leveraging cGAS/STING signaling to enhance the efficacy of immunotherapies and address tumor-mediated immune suppression, providing insights into future directions for personalized cancer treatments.
{"title":"cGAS/STING signaling pathway in gynecological malignancies: From molecular mechanisms to therapeutic values.","authors":"Danyang Zhang, Bingxue Zhang","doi":"10.3389/fimmu.2025.1525736","DOIUrl":"10.3389/fimmu.2025.1525736","url":null,"abstract":"<p><p>Gynecological cancers, including cervical, ovarian, and endometrial malignancies, remain a significant global health burden, exacerbated by disparities in access to preventive measures such as HPV vaccination and routine screening. The cGAS/STING signaling pathway, a pivotal mechanism in innate immunity, detects cytosolic DNA from pathogens or cellular damage, triggering immune responses via type I interferons and inflammatory cytokines. This pathway's dual role in gynecological cancers, either promoting antitumor immunity or facilitating tumor immune evasion, makes it a compelling target for innovative therapies. The article outlines cGAS/STING's influence on tumor microenvironments, immune surveillance, and inflammation, with emphasis on molecular mechanisms driving cancer progression. It explores interactions between DNA damage response pathways and immune modulation, highlighting the impact of cGAS/STING activation or suppression in ovarian, cervical, and endometrial cancers. The therapeutic potential of STING agonists, PARP inhibitors, and targeted immunotherapies is reviewed, demonstrating how these approaches can boost immune responses, counteract chemotherapy resistance, and improve patient outcomes. The study also discusses strategies for leveraging cGAS/STING signaling to enhance the efficacy of immunotherapies and address tumor-mediated immune suppression, providing insights into future directions for personalized cancer treatments.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1525736"},"PeriodicalIF":5.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30eCollection Date: 2025-01-01DOI: 10.3389/fimmu.2025.1526296
Yifu Shu, Jing Li
Background: Glioblastoma, associated with poor prognosis and impaired immune function, shows potential interactions between newly identified disulfidptosis mechanisms and T cell exhaustion, yet these remain understudied.
Methods: Key genes were identified using Lasso regression, followed by multivariate analysis to develop a prognostic model. Single-cell pseudotemporal analysis explored disulfidptosis T-cell exhaustion (Tex) signaling in cell differentiation. Immune infiltration was assessed via ssGSEA, while transwell assays and immunofluorescence examined the effects of disulfidptosis-Tex genes on glioma cell behavior and immune response.
Results: Eleven disulfidptosis-Tex genes were found critical for glioblastoma survival outcomes. This gene set underpinned a model predicting patient prognosis. Single-cell analysis showed high disulfidptosis-Tex activity in endothelial cells. Memory T cell populations were linked to these genes. SMC4 inhibition reduced LN299 cell migration and increased chemotherapy sensitivity, decreasing CD4 and CD8 T cell activation.
Conclusions: Disulfidptosis-Tex genes are pivotal in glioblastoma progression and immune interactions, offering new avenues for improving anti-glioblastoma therapies through modulation of T cell exhaustion.
{"title":"Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment.","authors":"Yifu Shu, Jing Li","doi":"10.3389/fimmu.2025.1526296","DOIUrl":"10.3389/fimmu.2025.1526296","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma, associated with poor prognosis and impaired immune function, shows potential interactions between newly identified disulfidptosis mechanisms and T cell exhaustion, yet these remain understudied.</p><p><strong>Methods: </strong>Key genes were identified using Lasso regression, followed by multivariate analysis to develop a prognostic model. Single-cell pseudotemporal analysis explored disulfidptosis T-cell exhaustion (Tex) signaling in cell differentiation. Immune infiltration was assessed via ssGSEA, while transwell assays and immunofluorescence examined the effects of disulfidptosis-Tex genes on glioma cell behavior and immune response.</p><p><strong>Results: </strong>Eleven disulfidptosis-Tex genes were found critical for glioblastoma survival outcomes. This gene set underpinned a model predicting patient prognosis. Single-cell analysis showed high disulfidptosis-Tex activity in endothelial cells. Memory T cell populations were linked to these genes. SMC4 inhibition reduced LN299 cell migration and increased chemotherapy sensitivity, decreasing CD4 and CD8 T cell activation.</p><p><strong>Conclusions: </strong>Disulfidptosis-Tex genes are pivotal in glioblastoma progression and immune interactions, offering new avenues for improving anti-glioblastoma therapies through modulation of T cell exhaustion.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1526296"},"PeriodicalIF":5.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}